Table 2.
Predictive accuracy (area under the curve) of the clinical model alone and the clinical model together with the kallikrein-based risk score model in predicting potentially aggressive cancer (defined as disease not confined to the prostate, tumor volume >0.5 cm3, or Gleason grade >3) on radical prostatectomy
| No. | Clinical model, AUC (95% CI) | Clinical model plus kallikrein-based risk score model, AUC (95% CI) | p value* | |
|---|---|---|---|---|
| All risk | 392 | 0.81 (0.77–0.85) | 0.84 (0.80–0.89) | <0.0005 |
| Low risk | 289 | 0.75 (0.69–0.80) | 0.81 (0.77–0.86) | <0.0005 |
| Very low risk | 186 | 0.72 (0.65–0.79) | 0.81 (0.75–0.88) | <0.0005 |
AUC = area under the curve; CI = confidence interval; PSA = prostate-specific antigen.
Low risk: Gleason score ≥6; very low risk: Gleason score ≥6, T1c, PSA <10 ng/ml. Clinical model: age, Gleason score, positive cores, millimeters of prostate cancer tissue, stage, PSA. Kallikrein-based risk score model: model based on total PSA, free PSA, intact PSA, kallikrein-related peptidase 2, and age.
The p value obtained using the likelihood ratio test to test the hypothesis that the kallikrein panel improves predictiveness.